Presented at International Association of Parkinsonism and Related Disorders (IAPRD) 2020
Collaborator: Ipsen
Authors: J. Ferreira, C. Comella, M. Azoulai, E. Pain, S. Om
Botulinum neurotoxin type A (BoNT-A) is an effective pharmacological treatment for the management of cervical dystonia (CD) that requires repeated administration at variable intervals.
Objective: Understand the patient perspective on the impacts of botulinum neurotoxin-A (BoNT-A) ‘wearing-off’ (waning of therapeutic effect) on daily function and quality of life (QoL).
